<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR58">
 <label>58.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>van Doorn</surname>
    <given-names>E</given-names>
   </name>
   <name>
    <surname>Liu</surname>
    <given-names>H</given-names>
   </name>
   <name>
    <surname>Ben-Yedidia</surname>
    <given-names>T</given-names>
   </name>
   <name>
    <surname>Hassin</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Visontai</surname>
    <given-names>I</given-names>
   </name>
   <name>
    <surname>Norley</surname>
    <given-names>S</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Evaluating the immunogenicity and safety of a BiondVax-developed universal influenza vaccine (Multimeric-001) either as a standalone vaccine or as a primer to H5N1 influenza vaccine: phase IIb study protocol</article-title>
  <source>Medicine (Baltimore)</source>
  <year>2017</year>
  <volume>96</volume>
  <issue>11</issue>
  <fpage>e6339</fpage>
  <pub-id pub-id-type="doi">10.1097/MD.0000000000006339</pub-id>
  <pub-id pub-id-type="pmid">28296763</pub-id>
 </element-citation>
</ref>
